Tectonic Therapeutic | AVRO

Stock Price
16.80
Daily Change
-0.47 -2.72%
Monthly
-27.46%
Yearly
-8.50%
Q3 Forecast
16.66

Peers Price Chg Day Year Date
Celltrion 169,000.00 -1,200.00 -0.71% -11.61% Sep/05
Cspc Pharmaceutical 11.19 0.36 3.32% 140.13% Sep/05
Sino Biopharmaceutical 8.91 0.52 6.20% 183.76% Sep/05
Takeda 4,574.00 33.00 0.73% 7.09% Sep/05
Zhangzhou Pientzehuang Pharmaceutical 203.87 0.94 0.46% 0.69% Sep/05
Kangmei Pharma 2.03 0 0% 15.34% Sep/05
Adcock Ingram Holdings 7,187.00 -13.00 -0.18% 10.77% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Divis Laboratories Ltd 6,009.00 -124.50 -2.03% 16.96% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Knight Therapeutics 6.44 0 0% 14.18% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
MacroGenics 2.00 0.06 3.09% -38.46% Sep/05
Dianthus Therapeutics 26.50 1.84 7.46% -0.45% Sep/05
Malin Corporation 8.00 0 0% 29.03% Sep/01
Medical Developments International 0.58 -0.01 -0.86% 36.90% Sep/05
Neuren Pharmaceuticals 20.48 0.50 2.50% 51.03% Sep/05
Organigram Holdings 2.28 0.08 3.64% -4.20% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Pharma Mar 88.40 -2.80 -3.07% 116.88% Sep/05
Qiagen NV 40.39 0.18 0.44% -1.38% Sep/06
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Laboratorios Farma 59.65 -0.10 -0.17% -26.18% Sep/05
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Sartorius 193.20 4.90 2.60% -23.42% Sep/06
Tilray 1.64 0.06 3.80% -25.45% Sep/05


Tectonic Therapeutic Inc. traded at $16.80 this Friday September 5th, decreasing $0.47 or 2.72 percent since the previous trading session. Looking back, over the last four weeks, Tectonic Therapeutic lost 27.46 percent. Over the last 12 months, its price fell by 8.50 percent. Looking ahead, we forecast Tectonic Therapeutic Inc. to be priced at 16.66 by the end of this quarter and at 16.25 in one year, according to Trading Economics global macro models projections and analysts expectations.

Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).